Long COVID, affecting 5-10% of COVID-19 patients, might be caused by the enduring presence of the virus in the body.
Research suggests that viral fragments, possibly live, linger and lead to symptoms. Addressing this involves antiviral treatments, enhanced public awareness, and preventive measures against reinfection.
Understanding Long COVID and Its Prevalence
About 5–10% of people infected with COVID-19 develop long COVID, experiencing symptoms that last three months or longer.
Scientists have suggested several biological mechanisms to explain long COVID. However, in a recent perspective article in the Medical Journal of Australia, we propose that long COVID may largely be caused by the virus itself persisting in the body.
Since the early days of the pandemic, researchers have recognized that SARS-CoV-2 — or its remnants — can remain in different tissues and organs long after the initial infection. This phenomenon is referred to as "viral persistence."

Credit: SciTechDaily.com
Evidence of Persistent Virus and Its Implications
While the long-term presence of residual viral fragments in some people's bodies is now well established, what remains less certain is whether live virus itself, not just old bits of virus, is lingering – and if so, whether this is what causes long COVID. This distinction is crucial because live virus can be targeted by specific antiviral approaches in ways that "dead" viral fragments cannot.
Viral persistence has two significant implications:
- when it occurs in some highly immunocompromised people, it is thought to be the source of new and substantially different-looking variants, such as JN.1
- it has the potential to continue to cause symptoms in many people in the wider population long beyond the acute illness. In other words, long COVID could be caused by a long infection.
Current Research Findings on Viral Persistence
While there remains no single study that confirms that persistent virus is the cause of long COVID, collectively several recent key papers make a compelling case.
In February, a study in Nature found a high number of people with mild COVID symptoms had extended periods of shedding the genetic material of the virus, so-called viral RNA, from their respiratory tract. Those with persistent shedding of this viral RNA – which almost certainly represents the presence of live virus – were at higher risk of long COVID.
Other key papers detected replicating viral RNA and proteins in blood fluid of patients years after their initial infection, a sign that the virus is likely replicating for long periods in some hidden reservoirs in the body, perhaps including blood cells.
Another study detected viral RNA in ten different tissue sites and blood samples 1–4 months after acute infection. This study found the risk of long COVID (measured four months following infection) was higher in those with persistently positive viral RNA.
The same study also gave clues about where in the body the persisting virus resides. The gastrointestinal tract is one site of considerable interest as a long-term viral hideout.
The Challenge of Proving Viral Replication
Earlier this month, further evidence of persistent virus increasing likelihood of long COVID has been published as part of the RECOVER initiative, a collaborative research project that aims to address the impacts of long COVID.
However, formal proof that virus capable of replicating can last for years in the body remains elusive. This is because isolating the live virus from reservoirs inside the body where the virus "hides" is technically challenging.
In its absence, we and other scientists argue the cumulative evidence is now sufficiently compelling to galvanise action.
Strategies to Address Long COVID
The obvious response to this is to fast-track trials of known antivirals for prevention and cure of long COVID.
This should include more left-field therapies such as the diabetes drug metformin. This has possible dual benefits in the context of long COVID:
- its antiviral properties, which have demonstrated surprising efficacy against long COVID
- as a potential therapeutic in treating impairments related to fatigue.
However, another major thrust should be the development of new drugs and the establishment of clinical trial platforms for rapid testing.
Science has uncovered exciting therapeutic options. But translating these into forms usable in the clinic is a large hurdle that requires support and investment from governments.
Raising Awareness and Preventing Long COVID
The notion of "long infection" as a contributor or even the driver of long COVID is a powerful message. It could help demystify the condition in the eyes of the wider community and increase awareness among the general public as well as medical professionals.
It should help raise awareness in the community of the importance of reducing rates of re-infection. It is not just your first infection, but each subsequent COVID infection carries a risk of long COVID.
Long COVID is common and isn't restricted to those at high risk of severe acute disease but affects all age groups. In one study, the highest impact was in those aged 30 to 49 years.
Preventive Measures and Future Outlook
So, for now, we all need to reduce our exposure to the virus with the tools available, a combination of:
- clean indoor air approaches. In its simplest form, this means being conscious of the importance of well-ventilated indoor spaces, opening the windows and improving airflow as COVID spreads through air. More sophisticated ways of ensuring indoor air is safe involve monitoring quality and filtering air in spaces that cannot be easily naturally ventilated
- using high-quality masks (that are well-fitting and don't let air in easily, such as N95-type masks) in settings where you don't have confidence of the quality of the indoor air and/or that are crowded
- testing, so you know when you're positive. Then, if you're eligible, you can get treatment. And you can be vigilant about protecting those around you with masks, staying at home where possible, and ventilating spaces
- staying up to date with COVID booster doses. Vaccines reduce long COVID and other post-COVID complications.
Hopefully one day there will be better treatments and even a cure for long COVID. But in the meantime, increased awareness of the biomedical basis of long COVID should prompt clinicians to take patients more seriously as they attempt to access the treatments and services that already exist.
Written by:
- Brendan Crabb, Director and CEO, Burnet Institute
- Gabriela Khoury, Theme Leader, Antiviral Immunity, Burnet Institute
- Michelle Scoullar, Senior Research Fellow, Burnet Institute
Adapted from an article originally published in The Conversation.
News
New mRNA therapy targets drug-resistant pneumonia
Bacteria that multiply on surfaces are a major headache in health care when they gain a foothold on, for example, implants or in catheters. Researchers at Chalmers University of Technology in Sweden have found [...]
Current Heart Health Guidelines Are Failing To Catch a Deadly Genetic Killer
New research reveals that standard screening misses most people with a common inherited cholesterol disorder. A Mayo Clinic study reports that current genetic screening guidelines overlook most people who have familial hypercholesterolemia, an inherited disorder that [...]
Scientists Identify the Evolutionary “Purpose” of Consciousness
Summary: Researchers at Ruhr University Bochum explore why consciousness evolved and why different species developed it in distinct ways. By comparing humans with birds, they show that complex awareness may arise through different neural architectures yet [...]
Novel mRNA therapy curbs antibiotic-resistant infections in preclinical lung models
Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have reported early success with a novel mRNA-based therapy designed to combat antibiotic-resistant bacteria. The findings, published in Nature Biotechnology, show that in [...]
New skin-permeable polymer delivers insulin without needles
A breakthrough zwitterionic polymer slips through the skin’s toughest barriers, carrying insulin deep into tissue and normalizing blood sugar, offering patients a painless alternative to daily injections. A recent study published in the journal Nature examines [...]
Multifunctional Nanogels: A Breakthrough in Antibacterial Strategies
Antibiotic resistance is a growing concern - from human health to crop survival. A new study successfully uses nanogels to target and almost entirely inhibit the bacteria P. Aeruginosa. Recently published in Angewandte Chemie, the study [...]
Nanoflowers rejuvenate old and damaged human cells by replacing their mitochondria
Biomedical researchers at Texas A&M University may have discovered a way to stop or even reverse the decline of cellular energy production—a finding that could have revolutionary effects across medicine. Dr. Akhilesh K. Gaharwar [...]
The Stunning New Push to Protect the Invisible 99% of Life
Scientists worldwide have joined forces to build the first-ever roadmap for conserving Earth’s vast invisible majority—microbes. Their new IUCN Specialist Group reframes conservation by elevating microbial life to the same urgency as plants and [...]
Scientists Find a Way to Help the Brain Clear Alzheimer’s Plaques Naturally
Scientists have discovered that the brain may have a built-in way to fight Alzheimer’s. By activating a protein called Sox9, researchers were able to switch on star-shaped brain cells known as astrocytes and turn them into [...]
Vision can be rebooted in adults with amblyopia, study suggests
Temporarily anesthetizing the retina briefly reverts the activity of the visual system to that observed in early development and enables growth of responses to the amblyopic eye, new research shows. In the common vision [...]
Ultrasound-activated Nanoparticles Kill Liver Cancer and Activate Immune System
A new ultrasound-guided nanotherapy wipes out liver tumors while training the immune system to keep them from coming back. The study, published in Nano Today, introduces a biodegradable nanoparticle system that combines sonodynamic therapy and cell [...]
Magnetic nanoparticles that successfully navigate complex blood vessels may be ready for clinical trials
Every year, 12 million people worldwide suffer a stroke; many die or are permanently impaired. Currently, drugs are administered to dissolve the thrombus that blocks the blood vessel. These drugs spread throughout the entire [...]
Reviving Exhausted T Cells Sparks Powerful Cancer Tumor Elimination
Scientists have discovered how tumors secretly drain the energy from T cells—the immune system’s main cancer fighters—and how blocking that process can bring them back to life. The team found that cancer cells use [...]
Very low LDL-cholesterol correlates to fewer heart problems after stroke
Brigham and Women's Hospital's TIMI Study Group reports that in patients with prior ischemic stroke, very low achieved LDL-cholesterol correlated with fewer major adverse cardiovascular events and fewer recurrent strokes, without an apparent increase [...]
“Great Unified Microscope” Reveals Hidden Micro and Nano Worlds Inside Living Cells
University of Tokyo researchers have created a powerful new microscope that captures both forward- and back-scattered light at once, letting scientists see everything from large cell structures to tiny nanoscale particles in a single shot. Researchers [...]
Breakthrough Alzheimer’s Drug Has a Hidden Problem
Researchers in Japan found that although the Alzheimer’s drug lecanemab successfully removes amyloid plaques from the brain, it does not restore the brain’s waste-clearing system within the first few months of treatment. The study suggests that [...]















